Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer

NCT ID NCT07751133

Not yet recruiting Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate cancer that has spread will be randomly assigned to receive either the full or half dose, alongside standard hormone therapy. The study will compare overall survival, fatigue levels, and how many men can stay on treatment without stopping due to side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Androgen Receptor Pathway Inhibitors (ARPI) at half the standard dose, combined with standard androgen deprivation therapy (ADT)
What this could lead to: If successful, this could show that a lower dose of hormone therapy is just as effective but with less fatigue, improving quality of life for men with metastatic prostate cancer.
What could go wrong: The trial is large and phase 3, but the lower dose might not be as effective in controlling the cancer, and the results may not apply to all patients. Side effects could still occur even at half dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRPC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome metastatic prostate carcinoma Neoplasm Metastasis prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC MHSPC PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.